Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?

References

• Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349(9063), 1436–1442 (1997).
   PubMed Web of Science ®Google Scholar
• World Health Organization Cross-national comparisons of the prevalences and correlates of mental disorders. WHO International Consortium in Psychiatric Epidemiology. Bull. World. Health. Organ. 78, 413–426 (2000).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the 21st Century. Annu. Rev. Clin. Psychol. 3, 137–158 (2007).
   PubMed Web of Science ®Google Scholar
• Burke KC, Burke JD Jr, Rae DS, Regier DA. Comparing age at onset of major depression and other psychiatric disorders by birth cohorts in five US community populations. Arch. Gen. Psychiatry 48(9), 789–795 (1991).
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Kupfer DJ, Frank E et al. Relationship of birth cohort and early age at onset of illness in a bipolar disorder case registry. Am. J. Psychiatry 160(9), 1636–1642 (2003).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Miyahara S, Marangell LB et al.; STEP-BD Investigators. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol. Psychiatry 55(9), 875–881 (2004).
   PubMed Web of Science ®Google Scholar
• Conus P, Ward J, Hallam KT et al. The proximal prodrome to first-episode mania – a new target for early intervention. Bipolar Disord. 10(5), 555–565 (2008).
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Jamison KR. Manic-Depressive Illness. Oxford University Press, NY, USA, 134–136 (1990).
   Google Scholar
• Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 12(8 Suppl. 13), 1–27 (2007).
   PubMedGoogle Scholar
• Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J. Affect. Disord. 68(2–3), 167–181 (2002).
   PubMed Web of Science ®Google Scholar
• Osby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58(9), 844–850 (2001).
   PubMed Web of Science ®Google Scholar
• Ehringer MA, Rhee SH, Young S, Corley R, Hewitt JK. Genetic and environmental contributions to common psychopathologies of childhood and adolescence: a study of twins and their siblings. J. Abnorm. Child Psychol. 34(1), 1–17 (2006).
   Google Scholar
• Merikangas KR, Chakravarti A, Moldin SO et al. Future of genetics of mood disorders research. Biol. Psychiatry 52(6), 457–477 (2002).
   PubMed Web of Science ®Google Scholar
• Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 157(10), 1552–1562 (2000).
   PubMed Web of Science ®Google Scholar
• Farmer A, Elkin A, McGuffin P. The genetics of bipolar affective disorder. Curr. Opin. Psychiatry 20(1), 8–12 (2007).
   Google Scholar
• Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder. Am. J. Med. Genet. C. Semin. Med. Genet. 123C(1), 48–58 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor L, Faraone SV, Tsuang MT. Family, twin, and adoption studies of bipolar disease. Curr. Psychiatry Rep. 4(2), 130–133 (2002).
   Google Scholar
• Weissman MM, Bland RC, Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276(4), 293–299 (1996).
   PubMed Web of Science ®Google Scholar
• Portanova JP, Zhang Y, Anderson GD et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin-6 production in vivo. J. Exp. Med. 184(3), 883–891 (1996).
   PubMed Web of Science ®Google Scholar
• Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin-6 in rat adjuvant arthritis. J. Clin. Invest. 97(11), 2672–2679 (1996).
   PubMed Web of Science ®Google Scholar
• Wang P, Zhu F, Konstantopoulos K. Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF-kappaB activation. Am. J. Physiol., Cell Physiol. 298(6), C1445–C1456 (2010).
   PubMed Web of Science ®Google Scholar
• Castell JV, Gómez-Lechón MJ, David M et al. Interleukin-6 is the major regulator of acute-phase protein synthesis in adult human hepatocytes. FEBS Lett. 242(2), 237–239 (1989).
   PubMed Web of Science ®Google Scholar
• Li SP, Liu TY, Goldman ND. cis-acting elements responsible for interleukin-6 inducible C-reactive protein gene expression. J. Biol. Chem. 265(7), 4136–4142 (1990).
   PubMed Web of Science ®Google Scholar
• Li SP, Goldman ND. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 35(28), 9060–9068 (1996).
   PubMed Web of Science ®Google Scholar
• Calder PC. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot. Essent. Fatty Acids 79(3–5), 101–108 (2008).
   PubMed Web of Science ®Google Scholar
• Bazan NG, Calandria JM, Serhan CN. Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. J. Lipid Res. 51(8), 2018–2031 (2010).
   PubMed Web of Science ®Google Scholar
• Groeger AL, Cipollina C, Cole MP et al. Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat. Chem. Biol. 6(6), 433–441 (2010).
   PubMed Web of Science ®Google Scholar
• Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am. J. Pathol. 177(4), 1576–1591 (2010).
   PubMed Web of Science ®Google Scholar
• Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278(17), 14677–14687 (2003).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Skwerer RG, Barna B et al. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res. 17(1), 41–47 (1986).
   PubMed Web of Science ®Google Scholar
• Lieb J, Karmali R, Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins. Leukot. Med. 10(4), 361–367 (1983).
   PubMedGoogle Scholar
• Nishino S, Ueno R, Ohishi K, Sakai T, Hayaishi O. Salivary prostaglandin concentrations: possible state indicators for major depression. Am. J. Psychiatry 146(3), 365–368 (1989).
   PubMed Web of Science ®Google Scholar
• Ohishi K, Ueno R, Nishino S, Sakai T, Hayaishi O. Increased level of salivary prostaglandins in patients with major depression. Biol. Psychiatry 23(4), 326–334 (1988).
   PubMed Web of Science ®Google Scholar
• Linnoila M, Whorton AR, Rubinow DR, Cowdry RW, Ninan PT, Waters RN. CSF prostaglandin levels in depressed and schizophrenic patients. Arch. Gen. Psychiatry 40(4), 405–406 (1983).
   PubMed Web of Science ®Google Scholar
• Rao JS, Ertley RN, DeMar JC Jr, Rapoport SI, Bazinet RP, Lee HJ. Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol. Psychiatry 12(2), 151–157 (2007).
   PubMed Web of Science ®Google Scholar
• Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol. Psychiatry 68(2), 140–147 (2010).
   PubMed Web of Science ®Google Scholar
• Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31(Suppl.), S157–S161 (1996).
   PubMed Web of Science ®Google Scholar
• Conklin SM, Manuck SB, Yao JK, Flory JD, Hibbeln JR, Muldoon MF. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom. Med. 69(9), 932–934 (2007).
   PubMed Web of Science ®Google Scholar
• Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: decreased omega-3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega-3 ratio in cholesteryl esters and phospholipids. J. Affect. Disord. 38(1), 35–46 (1996).
   PubMed Web of Science ®Google Scholar
• McNamara RK, Jandacek R, Rider T, Tso P, Dwivedi Y, Pandey GN. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J. Affect. Disord. 126(1–2), 303–311 (2010).
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67(5), 446–457 (2010).
   PubMed Web of Science ®Google Scholar
• Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71(2), 171–186 (2009).
   PubMed Web of Science ®Google Scholar
• Kling MA, Alesci S, Csako G et al. Sustained low-grade proinflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute-phase proteins C-reactive protein and serum amyloid A. Biol. Psychiatry 62(4), 309–313 (2007).
   PubMed Web of Science ®Google Scholar
• Kop WJ, Gottdiener JS, Tangen CM et al. Inflammation and coagulation factors in persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am. J. Cardiol. 89(4), 419–424 (2002).
   PubMed Web of Science ®Google Scholar
• Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22(4), 370–379 (2000).
   PubMed Web of Science ®Google Scholar
• Penninx BW, Kritchevsky SB, Yaffe K et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol. Psychiatry 54(5), 566–572 (2003).
   PubMed Web of Science ®Google Scholar
• Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom. Med. 65(3), 347–356 (2003).
   PubMed Web of Science ®Google Scholar
• Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 164(9), 1010–1014 (2004).
   PubMedGoogle Scholar
• Liukkonen T, Silvennoinen–Kassinen S, Jokelainen J et al. The association between C-reactive protein levels and depression: Results from the northern Finland 1966 birth cohort study. Biol. Psychiatry 60(8), 825–830 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 70(8), 1078–1090 (2009).
   PubMed Web of Science ®Google Scholar
• Noponen M, Sanfilipo M, Samanich K et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry 34(9), 641–649 (1993).
   PubMed Web of Science ®Google Scholar
• Chiu CC, Huang SY, Su KP et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur. Neuropsychopharmacol. 13(2), 99–103 (2003).
   PubMed Web of Science ®Google Scholar
• Sublette ME, Bosetti F, DeMar JC et al. Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disord. 9(7), 759–765 (2007).
   Google Scholar
• Brietzke E, Stertz L, Fernandes BS et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 116(3), 214–217 (2009).
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29(2), 141–152 (1995).
   PubMed Web of Science ®Google Scholar
• Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between proinflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 104(1–3), 91–95 (2007).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 90(2–3), 263–267 (2006).
   PubMed Web of Science ®Google Scholar
• Ortiz-Domínguez A, Hernández ME, Berlanga C et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 9(6), 596–602 (2007).
   PubMed Web of Science ®Google Scholar
• Breunis MN, Kupka RW, Nolen WA et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol. Psychiatry 53(2), 157–165 (2003).
   PubMed Web of Science ®Google Scholar
• Padmos RC, Hillegers MH, Knijff EM et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 65(4), 395–407 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai SY, Chen KP, Yang YY et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol. Psychiatry 45(8), 989–994 (1999).
   PubMed Web of Science ®Google Scholar
• Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J. Affect. Disord. 64(2–3), 185–193 (2001).
   PubMed Web of Science ®Google Scholar
• Cunha AB, Andreazza AC, Gomes FA et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 258(5), 300–304 (2008).
   PubMed Web of Science ®Google Scholar
• Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(2), 370–372 (2007).
   PubMed Web of Science ®Google Scholar
• Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M. Serological observations in patients suffering from acute manic episodes. Hum. Psychopharmacol. 17(4), 175–179 (2002).
   PubMed Web of Science ®Google Scholar
• Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J. Affect. Disord. 136(1–2), 110–116 (2012).
   PubMed Web of Science ®Google Scholar
• De Berardis D, Conti CM, Campanella D et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int. J. Immunopathol. Pharmacol. 21(2), 319–324 (2008).
   Google Scholar
• Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(4), 952–955 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Collinger KA, Lotrich F et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J. Child Adolesc. Psychopharmacol. 21(5), 479–484 (2011).
   PubMed Web of Science ®Google Scholar
• Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. Cytokine production in bipolar affective disorder patients under lithium treatment. J. Affect. Disord. 82(2), 309–313 (2004).
   PubMed Web of Science ®Google Scholar
• Padmos RC, Bekris L, Knijff EM et al. A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biol. Psychiatry 56(7), 476–482 (2004).
   PubMed Web of Science ®Google Scholar
• Kupka RW, Nolen WA, Post RM et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol. Psychiatry 51(4), 305–311 (2002).
   PubMed Web of Science ®Google Scholar
• Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40(4), 171–176 (1999).
   PubMed Web of Science ®Google Scholar
• Stübner S, Schön T, Padberg F et al. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neurosci. Lett. 259(3), 145–148 (1999).
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J. Affect. Disord. 79(1–3), 285–289 (2004).
   PubMed Web of Science ®Google Scholar
• Söderlund J, Olsson SK, Samuelsson M et al. Elevation of cerebrospinal fluid interleukin-1b in bipolar disorder. J. Psychiatry Neurosci. 36(2), 114–118 (2011).
   PubMed Web of Science ®Google Scholar
• Kim HW, Rapoport SI, Rao JS. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol. Psychiatry 16(4), 419–428 (2011).
   PubMed Web of Science ®Google Scholar
• Maida ME, Hurley SD, Daeschner JA, Moore AH, O’Banion MK. Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res. 1103(1), 164–172 (2006).
   PubMed Web of Science ®Google Scholar
• Ross BM, Hughes B, Kish SJ, Warsh JJ. Serum calcium-independent phospholipase A2 activity in bipolar affective disorder. Bipolar Disord. 8(3), 265–270 (2006).
   PubMed Web of Science ®Google Scholar
• McNamara RK, Jandacek R, Rider T et al. Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res. 160(3), 285–299 (2008).
   PubMed Web of Science ®Google Scholar
• Igarashi M, Ma K, Gao F et al. Brain lipid concentrations in bipolar disorder. J. Psychiatr. Res. 44(3), 177–182 (2010).
   Google Scholar
• Dean B, Tawadros N, Scarr E, Gibbons AS. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J. Affect. Disord. 120(1–3), 245–248 (2010).
   Google Scholar
• Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar-disorder patients. Mol. Psychiatry 15(4), 384–392 (2010).
   PubMed Web of Science ®Google Scholar
• Lindqvist D, Janelidze S, Hagell P et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol. Psychiatry 66(3), 287–292 (2009).
   PubMed Web of Science ®Google Scholar
• Tonelli LH, Stiller J, Rujescu D et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr. Scand. 117(3), 198–206 (2008).
   PubMed Web of Science ®Google Scholar
• Pandey GN, Rizavi HS, Ren X et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J. Psychiatr. Res. 46(1), 57–63 (2012).
   PubMed Web of Science ®Google Scholar
• Lalovic A, Levy E, Canetti L, Sequeira A, Montoudis A, Turecki G. Fatty acid composition in postmortem brains of people who completed suicide. J. Psychiatry Neurosci. 32(5), 363–370 (2007).
   PubMed Web of Science ®Google Scholar
• McNamara RK, Jandacek R, Rider T et al. Fatty acid composition of the postmortem prefrontal cortex of adolescent male and female suicide victims. Prostaglandins Leukot. Essent. Fatty Acids 80(1), 19–26 (2009).
   PubMed Web of Science ®Google Scholar
• Garland MR, Hallahan B, McNamara M et al. Lipids and essential fatty acids in patients presenting with self-harm. Br. J. Psychiatry 190, 112–117 (2007).
   PubMed Web of Science ®Google Scholar
• Huan M, Hamazaki K, Sun Y et al. Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. Biol. Psychiatry 56(7), 490–496 (2004).
   PubMed Web of Science ®Google Scholar
• Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ. Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am. J. Psychiatry 163(6), 1100–1102 (2006).
   PubMed Web of Science ®Google Scholar
• Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of cytokine-induced depression. Brain Behav. Immun. 16(5), 575–580 (2002).
   PubMed Web of Science ®Google Scholar
• Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon-α. N. Engl. J. Med. 344(13), 961–966 (2001).
   PubMed Web of Science ®Google Scholar
• Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27(1), 24–31 (2006).
   PubMed Web of Science ®Google Scholar
• Dan AA, Crone C, Wise TN et al. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics 48(3), 223–229 (2007).
   PubMed Web of Science ®Google Scholar
• Préau M, Marcellin F, Spire B et al. Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV–HCV coinfected patients. J. Clin. Gastroenterol. 42(1), 92–96 (2008).
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Labile anger during interferon-α treatment is associated with a polymorphism in tumor necrosis factor-α. Clin. Neuropharmacol. 33(4), 191–197 (2010).
   PubMed Web of Science ®Google Scholar
• Constant A, Castera L, Dantzer R et al. Mood alterations during interferon-α therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J. Clin. Psychiatry 66(8), 1050–1057 (2005).
   PubMed Web of Science ®Google Scholar
• Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. Cytokine-induced depression during IFN-α treatment: the role of IL-6 and sleep quality. Brain Behav. Immun. 23(8), 1109–1116 (2009).
   PubMed Web of Science ®Google Scholar
• Raison CL, Borisov AS, Majer M et al. Activation of central nervous system inflammatory pathways by interferon-α: relationship to monoamines and depression. Biol. Psychiatry 65(4), 296–303 (2009).
   PubMed Web of Science ®Google Scholar
• Reichenberg A, Yirmiya R, Schuld A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58(5), 445–452 (2001).
   PubMed Web of Science ®Google Scholar
• Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch. Gen. Psychiatry 60(10), 1009–1014 (2003).
   PubMed Web of Science ®Google Scholar
• Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9(1), 46–56 (2008).
   PubMed Web of Science ®Google Scholar
• Simen BB, Duman CH, Simen AA, Duman RS. TNF-α signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol. Psychiatry 59(9), 775–785 (2006).
   PubMed Web of Science ®Google Scholar
• Chourbaji S, Urani A, Inta I et al. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol. Dis. 23(3), 587–594 (2006).
   PubMed Web of Science ®Google Scholar
• Felger JC, Alagbe O, Hu F et al. Effects of interferon-α on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol. Psychiatry 62(11), 1324–1333 (2007).
   PubMed Web of Science ®Google Scholar
• Hayley S, Brebner K, Lacosta S, Merali Z, Anisman H. Sensitization to the effects of tumor necrosis factor-α: neuroendocrine, central monoamine, and behavioral variations. J. Neurosci. 19(13), 5654–5665 (1999).
   PubMed Web of Science ®Google Scholar
• McNamara RK, Jandacek R, Rider T, Tso P, Cole-Strauss A, Lipton JW. Omega-3 fatty acid deficiency increases constitutive proinflammatory cytokine production in rats: relationship with central serotonin turnover. Prostaglandins Leukot. Essent. Fatty Acids 83(4–6), 185–191 (2010).
   PubMed Web of Science ®Google Scholar
• Mingam R, Moranis A, Bluthé RM et al. Uncoupling of interleukin-6 from its signalling pathway by dietary n-3-polyunsaturated fatty acid deprivation alters sickness behaviour in mice. Eur. J. Neurosci. 28(9), 1877–1886 (2008).
   PubMed Web of Science ®Google Scholar
• DeMar JC Jr, Ma K, Bell JM, Igarashi M, Greenstein D, Rapoport SI. One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats. J. Lipid Res. 47(1), 172–180 (2006).
   PubMed Web of Science ®Google Scholar
• Skelin I, Kovacevic T, Sato H, Diksic M. Upregulated arachidonic acid signalling in the olfactory bulbectomized rat model of depression. Neurochem. Int. 58(4), 483–488 (2011).
   Google Scholar
• Song C, Zhang XY, Manku M. Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J. Neurosci. 29(1), 14–22 (2009).
   PubMed Web of Science ®Google Scholar
• Green P, Gispan-Herman I, Yadid G. Increased arachidonic acid concentration in the brain of Flinders Sensitive Line rats, an animal model of depression. J. Lipid Res. 46(6), 1093–1096 (2005).
   Google Scholar
• Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J. Cardiol. 53(3), 317–333 (2009).
   PubMed Web of Science ®Google Scholar
• Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N. Engl. J. Med. 343(16), 1139–1147 (2000).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336(14), 973–979 (1997).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101(15), 1767–1772 (2000).
   PubMed Web of Science ®Google Scholar
• Ozdemir O, Gundogdu F, Karakelleoglu S et al. Comparison of serum levels of inflammatory markers and allelic variant of interleukin-6 in patients with acute coronary syndrome and stable angina pectoris. Coron. Artery Dis. 19(1), 15–19 (2008).
   Google Scholar
• Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286(17), 2107–2113 (2001).
   PubMed Web of Science ®Google Scholar
• Harris WS. The omega-3 index as a risk factor for coronary heart disease. Am. J. Clin. Nutr. 87(6), 1997S–2002S (2008).
   PubMed Web of Science ®Google Scholar
• McNamara RK. Membrane omega-3 fatty acid deficiency as a preventable risk factor for comorbid coronary heart disease in major depressive disorder. Cardiovasc. Psychiatry Neurol. 9, 1–13 (2009).
   Google Scholar
• McElroy SL, Frye MA, Suppes T et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J. Clin. Psychiatry 63(3), 207–213 (2002).
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Frank E, Houck PR et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J. Clin. Psychiatry 63(6), 528–533 (2002).
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 7(5), 424–430 (2005).
   PubMed Web of Science ®Google Scholar
• Wang PW, Sachs GS, Zarate CA et al. Overweight and obesity in bipolar disorders. J. Psychiatr. Res. 40(8), 762–764 (2006).
   PubMed Web of Science ®Google Scholar
• Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann. Clin. Psychiatry 20(3), 131–137 (2008).
   PubMed Web of Science ®Google Scholar
• Hansen D, Dendale P, Beelen M et al. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to nonobese, Type 2 diabetes patients. Eur. J. Appl. Physiol. 109(3), 397–404 (2010).
   PubMed Web of Science ®Google Scholar
• Stelzer I, Zelzer S, Raggam RB et al. Link between leptin and interleukin-6 levels in the initial phase of obesity related inflammation. Transl. Res. 159(2), 118–124 (2012).
   PubMed Web of Science ®Google Scholar
• Goodwin RD, Jacobi F, Thefeld W. Mental disorders and asthma in the community. Arch. Gen. Psychiatry 60(11), 1125–1130 (2003).
   PubMed Web of Science ®Google Scholar
• Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst. Rev. 3, CD004851 (2007).
   Google Scholar
• Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 63(3), 332–339 (2006).
   PubMed Web of Science ®Google Scholar
• Baumer FM, Howe M, Gallelli K, Simeonova DI, Hallmayer J, Chang KD. A pilot study of antidepressant-induced mania in pediatric bipolar disorder: characteristics, risk factors, and the serotonin transporter gene. Biol. Psychiatry 60(9), 1005–1012 (2006).
   PubMed Web of Science ®Google Scholar
• Cicero D, El-Mallakh RS, Holman J, Robertson J. Antidepressant exposure in bipolar children. Psychiatry 66(4), 317–322 (2003).
   PubMed Web of Science ®Google Scholar
• Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J. Affect. Disord. 82(1), 149–158 (2004).
   PubMed Web of Science ®Google Scholar
• Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch. Pediatr. Adolesc. Med. 158(8), 773–780 (2004).
   PubMed Web of Science ®Google Scholar
• Findling RL, Frazier TW, Youngstrom EA et al. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. J. Clin. Psychiatry 68(5), 781–788 (2007).
   PubMed Web of Science ®Google Scholar
• Geller B, Cooper TB, Zimerman B et al. Lithium for prepubertal depressed children with family history predictors of future bipolarity: a double-blind, placebo-controlled study. J. Affect. Disord. 51(2), 165–175 (1998).
   PubMedGoogle Scholar
• Verrotti A, la Torre R, Trotta D, Mohn A, Chiarelli F. Valproate-induced insulin resistance and obesity in children. Horm. Res. 71(3), 125–131 (2009).
   PubMed Web of Science ®Google Scholar
• Fraguas D, Correll CU, Merchán-Naranjo J et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur. Neuropsychopharmacol. 21(8), 621–645 (2011).
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 9(4), 394–412 (2007).
   PubMed Web of Science ®Google Scholar
• Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch. Gen. Psychiatry 64(4), 442–455 (2007).
   PubMed Web of Science ®Google Scholar
• Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J. Affect. Disord. 124(3), 228–234 (2010).
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16), 1765–1773 (2009).
   PubMed Web of Science ®Google Scholar
• Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav. Immun. 16(5), 569–574 (2002).
   PubMed Web of Science ®Google Scholar
• Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 5(4), 401–412 (2002).
   PubMed Web of Science ®Google Scholar
• Yirmiya R, Pollak Y, Barak O et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 24(5), 531–544 (2001).
   PubMed Web of Science ®Google Scholar
• Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum. 42(12), 2561–2568 (1999).
   PubMedGoogle Scholar
• Porterfield VM, Zimomra ZR, Caldwell EA, Camp RM, Gabella KM, Johnson JD. Rat strain differences in restraint stress-induced brain cytokines. Neuroscience 188, 48–54 (2011).
   Google Scholar
• Lee HJ, Rao JS, Ertley RN, Chang L, Rapoport SI, Bazinet RP. Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl.) 190(1), 103–115 (2007).
   PubMedGoogle Scholar
• Lee HJ, Rao JS, Chang L, Rapoport SI, Kim HW. Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to ‘switching’ in bipolar disorder? Mol. Psychiatry 15(6), 602–614 (2010).
   Google Scholar
• Rao JS, Lee HJ, Rapoport SI, Bazinet RP. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol. Psychiatry 13(6), 585–596 (2008).
   PubMed Web of Science ®Google Scholar
• Post RM, Altshuler LL, Leverich GS et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br. J. Psychiatry 189, 124–131 (2006).
   PubMed Web of Science ®Google Scholar
• Jazayeri S, Keshavarz SA, Tehrani-Doost M et al. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1β and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res. 178(1), 112–115 (2010).
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Bosmans E et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34(4), 301–309 (1995).
   PubMed Web of Science ®Google Scholar
• Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 35(3), 123–127 (1997).
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment-resistant depression. Cytokine 9(11), 853–858 (1997).
   PubMed Web of Science ®Google Scholar
• Müller N, Schwarz MJ, Dehning S et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11(7), 680–684 (2006).
   PubMed Web of Science ®Google Scholar
• Musil R, Schwarz MJ, Riedel M et al. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-β levels in major depression – no influence of celecoxib treatment. J. Affect. Disord. 134(1–3), 217–225 (2011).
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Jafari S, Raisi F et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double-blind and placebo-controlled trial. Depress. Anxiety 26(7), 607–611 (2009).
   PubMed Web of Science ®Google Scholar
• Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int. Clin. Psychopharmacol. 21(4), 227–231 (2006).
   PubMed Web of Science ®Google Scholar
• Jazayeri S, Tehrani-Doost M, Keshavarz SA et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust. N. Z. J. Psychiatry 42(3), 192–198 (2008).
   PubMed Web of Science ®Google Scholar
• Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J. Clin. Psychopharmacol. 32(1), 61–64 (2012).
   PubMed Web of Science ®Google Scholar
• Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 59(10), 913–919 (2002).
   PubMed Web of Science ®Google Scholar
• McNamara RK, Sullivan J, Richtand NM. Omega-3 fatty acid deficiency augments amphetamine-induced behavioral sensitization in adult mice: prevention by chronic lithium treatment. J. Psychiatr. Res. 42(6), 458–468 (2008).
   PubMed Web of Science ®Google Scholar
• Rapoport SI. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot. Essent. Fatty Acids 79(3–5), 153–156 (2008).
   PubMed Web of Science ®Google Scholar
• Basselin M, Kim HW, Chen M et al. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J. Lipid Res. 51(5), 1049–1056 (2010).
   PubMedGoogle Scholar
• Rapoport SI, Basselin M, Kim HW, Rao JS. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res. Rev. 61(2), 185–209 (2009).
   PubMedGoogle Scholar
• Knijff EM, Breunis MN, Kupka RW et al. An imbalance in the production of IL-1β and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 9(7), 743–753 (2007).
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J. Psychiatr. Res. 33(4), 335–340 (1999).
   PubMed Web of Science ®Google Scholar
• Nery FG, Monkul ES, Hatch JP et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 23(2), 87–94 (2008).
   PubMed Web of Science ®Google Scholar
• Stolk P, Souverein PC, Wilting I et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot. Essent. Fatty Acids 82(1), 9–14 (2010).
   PubMed Web of Science ®Google Scholar
• Clayton EH, Hanstock TL, Hirneth SJ Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur. J. Clin. Nutr. 63(8), 1037–1040 (2009).
   PubMed Web of Science ®Google Scholar
• Stoll AL, Severus WE, Freeman MP et al. Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 56(5), 407–412 (1999).
   PubMed Web of Science ®Google Scholar
• Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 32(8), 1715–1726 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia MC, Kim HY. Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Res. 768(1–2), 43–48 (1997).
   PubMed Web of Science ®Google Scholar
• Nilsson CL, Hellstrand M, Ekman A, Eriksson E. Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent. Br. J. Pharmacol. 124(8), 1651–1658 (1998).
   PubMed Web of Science ®Google Scholar
• Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 353(6340), 164–167 (1991).
   PubMed Web of Science ®Google Scholar
• Qu Y, Chang L, Klaff J, Balbo A, Rapoport SI. Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (+/−)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). Neuropsychopharmacology 28(2), 244–252 (2003).
   PubMedGoogle Scholar
• Basselin M, Chang L, Bell JM, Rapoport SI. Chronic lithium chloride administration to unanesthetized rats attenuates brain dopamine D2-like receptor-initiated signaling via arachidonic acid. Neuropsychopharmacology 30(6), 1064–1075 (2005).
   PubMedGoogle Scholar
• Bhattacharjee AK, Chang L, White L, Bazinet RP, Rapoport SI. d-amphetamine stimulates D2 dopamine receptor-mediated brain signaling involving arachidonic acid in unanesthetized rats. J. Cereb. Blood Flow Metab. 26(11), 1378–1388 (2006).
   PubMedGoogle Scholar
• Kim HW, Cheon Y, Modi HR, Rapoport SI, Rao JS. Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain. Psychopharmacology (Berl.) 222(4), 663–674 (2012).
   PubMed Web of Science ®Google Scholar
• Cheon Y, Park JY, Modi HR et al. Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E2 concentration in rat brain. J. Neurochem. 119(2), 364–376 (2011).
   PubMed Web of Science ®Google Scholar
• Bian Q, Kato T, Monji A et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-γ. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(1), 42–48 (2008).
   PubMed Web of Science ®Google Scholar
• Kato T, Monji A, Hashioka S, Kanba S. Risperidone significantly inhibits interferon-γ-induced microglial activation in vitro. Schizophr. Res. 92(1–3), 108–115 (2007).
   PubMed Web of Science ®Google Scholar
• Sugino H, Futamura T, Mitsumoto Y, Maeda K, Marunaka Y. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(2), 303–307 (2009).
   PubMed Web of Science ®Google Scholar
• McNamara RK, Jandacek R, Rider T, Tso P. Chronic risperidone normalizes elevated proinflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats. Eur. J. Pharmacol. 652(1–3), 152–156 (2011).
   Google Scholar
• Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 20(6), 532–545 (2006).
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 90(1–3), 179–185 (2007).
   PubMed Web of Science ®Google Scholar
• Berger GE, Proffitt TM, McConchie M et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry 68(12), 1867–1875 (2007).
   PubMed Web of Science ®Google Scholar
• Arango V, Underwood MD, Mann JJ. Serotonin brain circuits involved in major depression and suicide. Prog. Brain Res. 136, 443–453 (2002).
   PubMed Web of Science ®Google Scholar
• Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(1), 85–102 (2003).
   PubMed Web of Science ®Google Scholar
• Rosa-Neto P, Diksic M, Okazawa H et al. Measurement of brain regional a-[11C]methyl-l-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch. Gen. Psychiatry 61(6), 556–563 (2004).
   PubMed Web of Science ®Google Scholar
• Barton DA, Esler MD, Dawood T et al. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch. Gen. Psychiatry 65(1), 38–46 (2008).
   PubMed Web of Science ®Google Scholar
• Lundmark J, Wålinder J, Alling C, Manniche PM, Dalgaard L. The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients. Eur. Neuropsychopharmacol. 4(1), 1–6 (1994).
   Google Scholar
• De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol. Psychiatry 33(8–9), 636–641 (1993).
   Google Scholar
• Potter WZ, Scheinin M, Golden RN et al. Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites. Arch. Gen. Psychiatry 42(12), 1171–1177 (1985).
   PubMedGoogle Scholar
• Sheline Y, Bardgett ME, Csernansky JG. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 17(1), 11–14 (1997).
   PubMed Web of Science ®Google Scholar
• Unceta N, Barrondo S, Ruiz de Azúa I et al. Determination of fluoxetine, norfluoxetine and their enantiomers in rat plasma and brain samples by liquid chromatography with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852(1–2), 519–528 (2007).
   PubMed Web of Science ®Google Scholar
• McNamara RK, Able JA, Rider T, Tso P, Jandacek R. Effect of chronic fluoxetine treatment on male and female rat erythrocyte and prefrontal cortex fatty acid composition. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(7), 1317–1321 (2010).
   Google Scholar
• Wang J, Dunn AJ. Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem. Int. 33(2), 143–154 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang J, Terreni L, De Simoni MG, Dunn AJ. Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem. Int. 38(4), 303–308 (2001).
   Google Scholar
• Clement HW, Buschmann J, Rex S et al. Effects of interferon-γ, interleukin-1β, and tumor necrosis factor-α on the serotonin metabolism in the nucleus raphe dorsalis of the rat. J. Neural Transm. 104(10), 981–991 (1997).
   PubMed Web of Science ®Google Scholar
• Sato T, Suzuki E, Yokoyama M, Semba J, Watanabe S, Miyaoka H. Chronic intraperitoneal injection of interferon-α reduces serotonin levels in various regions of rat brain, but does not change levels of serotonin transporter mRNA, nitrite or nitrate. Psychiatry Clin. Neurosci. 60(4), 499–506 (2006).
   PubMed Web of Science ®Google Scholar
• Hayley S, Lacosta S, Merali Z, van Rooijen N, Anisman H. Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: sensitization and cross-sensitization effects. Eur. J. Neurosci. 13(6), 1155–1165 (2001).
   Google Scholar
• Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49(5), 391–404 (2001).
   PubMed Web of Science ®Google Scholar
• Ströhle A, Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 36(Suppl. 3), S207–S214 (2003).
   Google Scholar
• Beishuizen A, Thijs LG. Endotoxin and the hypothalamo–pituitary–adrenal (HPA) axis. J. Endotoxin Res. 9(1), 3–24 (2003).
   PubMedGoogle Scholar
• Grinevich V, Ma XM, Herman JP, Jezova D, Akmayev I, Aguilera G. Effect of repeated lipopolysaccharide administration on tissue cytokine expression and hypothalamic–pituitary–adrenal axis activity in rats. J. Neuroendocrinol. 13(8), 711–723 (2001).
   PubMed Web of Science ®Google Scholar
• Jankord R, Zhang R, Flak JN, Solomon MB, Albertz J, Herman JP. Stress activation of IL-6 neurons in the hypothalamus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299(1), R343–R351 (2010).
   PubMed Web of Science ®Google Scholar
• Frank MG, Miguel ZD, Watkins LR, Maier SF. Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav. Immun. 24(1), 19–30 (2010).
   PubMed Web of Science ®Google Scholar
• Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. NY Acad. Sci. 1179, 86–105 (2009).
   PubMed Web of Science ®Google Scholar
• Pluess TT, Hayoz D, Berger MM et al. Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive Care Med. 33(5), 789–797 (2007).
   PubMed Web of Science ®Google Scholar
• Michaeli B, Berger MM, Revelly JP, Tappy L, Chioléro R. Effects of fish oil on the neuroendocrine responses to an endotoxin challenge in healthy volunteers. Clin. Nutr. 26(1), 70–77 (2007).
   Google Scholar
• Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 122(2), 155–170 (2011).
   PubMed Web of Science ®Google Scholar
• Chwastiak LA, Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatr. Clin. North Am. 30(4), 803–817 (2007).
   PubMed Web of Science ®Google Scholar
• Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am. J. Psychiatry 159(11), 1862–1868 (2002).
   PubMed Web of Science ®Google Scholar
• Iacovides A, Andreoulakis E. Bipolar disorder and resembling special psychopathological manifestations in multiple sclerosis: a review. Curr. Opin. Psychiatry 24(4), 336–340 (2011).
   PubMed Web of Science ®Google Scholar
• Scolozzi R, Boccafogli A, Tola MR et al. T-cell phenotypic profiles in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients. J. Neurol. Sci. 108(1), 93–98 (1992).
   Google Scholar
• Trotter JL, Clifford DB, Anderson CB, van der Veen RC, Hicks BC, Banks G. Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis. N. Engl. J. Med. 318(18), 1206 (1988).
   PubMedGoogle Scholar
• Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T-cell networks in patients with bipolar disorder. Brain Behav. Immun. 25(6), 1206–1213 (2011).
   PubMed Web of Science ®Google Scholar
• Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol. Psychiatry 10(3), 309–322 (2005).
   PubMed Web of Science ®Google Scholar
• Tkachev D, Mimmack ML, Ryan MM et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362(9386), 798–805 (2003).
   PubMed Web of Science ®Google Scholar
• Regenold WT, Phatak P, Marano CM, Gearhart L, Viens CH, Hisley KC. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res. 151(3), 179–188 (2007).
   PubMed Web of Science ®Google Scholar
• Hasan KM, Gupta RK, Santos RM, Wolinsky JS, Narayana PA. Diffusion tensor fractional anisotropy of the normal-appearing seven segments of the corpus callosum in healthy adults and relapsing-remitting multiple sclerosis patients. J. Magn. Reson. Imaging 21(6), 735–743 (2005).
   PubMedGoogle Scholar
• Benedetti F, Absinta M, Rocca MA et al. Tract-specific white matter structural disruption in patients with bipolar disorder. Bipolar Disord. 13(4), 414–424 (2011).
   PubMed Web of Science ®Google Scholar
• Heng S, Song AW, Sim K. White matter abnormalities in bipolar disorder: insights from diffusion tensor imaging studies. J. Neural Transm. 117(5), 639–654 (2010).
   PubMed Web of Science ®Google Scholar
• Zanetti MV, Jackowski MP, Versace A et al. State-dependent microstructural white matter changes in bipolar I depression. Eur. Arch. Psychiatry Clin. Neurosci. 259(6), 316–328 (2009).
   Google Scholar
• Wu F, Tang Y, Xu K et al. Whiter matter abnormalities in medication-naive subjects with a single short-duration episode of major depressive disorder. Psychiatry Res. 191(1), 80–83 (2011).
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang X, Xiao J, Zhong M, Liao J, Yao S. Altered white matter integrity in first-episode, treatment-naive young adults with major depressive disorder: a tract-based spatial statistics study. Brain Res. 1369, 223–229 (2011).
   PubMed Web of Science ®Google Scholar
• Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur. J. Immunol. 28(7), 2178–2187 (1998).
   PubMed Web of Science ®Google Scholar
• Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur. J. Immunol. 28(5), 1727–1737 (1998).
   PubMed Web of Science ®Google Scholar
• Stolp HB, Dziegielewska KM, Ek CJ, Potter AM, Saunders NR. Long-term changes in blood–brain barrier permeability and white matter following prolonged systemic inflammation in early development in the rat. Eur. J. Neurosci. 22(11), 2805–2816 (2005).
   PubMed Web of Science ®Google Scholar
• Stolp HB, Ek CJ, Johansson PA et al. Factors involved in inflammation-induced developmental white matter damage. Neurosci. Lett. 451(3), 232–236 (2009).
   Google Scholar
• Tuzun F, Kumral A, Dilek M et al. Maternal omega-3 fatty acid supplementation protects against lipopolysaccharide-induced white matter injury in the neonatal rat brain. J. Matern. Fetal. Neonatal. Med. 25(6), 849–854 (2012).
   PubMed Web of Science ®Google Scholar
• Ward RE, Huang W, Curran OE, Priestley JV, Michael-Titus AT. Docosahexaenoic acid prevents white matter damage after spinal cord injury. J. Neurotrauma 27(10), 1769–1780 (2010).
   Google Scholar
• Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch. Gen. Psychiatry 65(9), 1017–1032 (2008).
   PubMed Web of Science ®Google Scholar
• Kempton MJ, Salvador Z, Munafò MR et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch. Gen. Psychiatry 68(7), 675–690 (2011).
   PubMed Web of Science ®Google Scholar
• Campbell LR, Pang Y, Ojeda NB, Zheng B, Rhodes PG, Alexander BT. Intracerebral lipopolysaccharide induces neuroinflammatory change and augmented brain injury in growth-restricted neonatal rats. Pediatr. Res. 71(6), 645–652 (2012).
   Google Scholar
• Hauss-Wegrzyniak B, Galons JP, Wenk GL. Quantitative volumetric analyses of brain magnetic resonance imaging from rat with chronic neuroinflammation. Exp. Neurol. 165(2), 347–354 (2000).
   PubMed Web of Science ®Google Scholar
• Carrasco E, Casper D, Werner P. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J. Neurosci. Res. 85(14), 3109–3117 (2007).
   Google Scholar
• Kawaguchi K, Hickey RW, Rose ME, Zhu L, Chen J, Graham SH. Cyclooxygenase-2 expression is induced in rat brain after kainate-induced seizures and promotes neuronal death in CA3 hippocampus. Brain Res. 1050(1–2), 130–137 (2005).
   PubMed Web of Science ®Google Scholar
• Rao JS, Kellom M, Kim HW, Rapoport SI, Reese EA. Neuroinflammation and synaptic loss. Neurochem. Res. 37(5), 903–910 (2012).
   PubMedGoogle Scholar
• Myint AM, Schwarz MJ, Müller N. The role of the kynurenine metabolism in major depression. J. Neural Transm. 119(2), 245–251 (2012).
   PubMed Web of Science ®Google Scholar
• Conklin SM, Gianaros PJ, Brown SM et al. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Neurosci. Lett. 421(3), 209–212 (2007).
   PubMed Web of Science ®Google Scholar
• Padmos RC, Van Baal GC, Vonk R et al. Genetic and environmental influences on proinflammatory monocytes in bipolar disorder: a twin study. Arch. Gen. Psychiatry 66(9), 957–965 (2009).
   PubMed Web of Science ®Google Scholar
• Pearce BD, Kruszon-Moran D, Jones JL. The relationship between Toxoplasma gondii infection and mood disorders in the third national health and nutrition survey. Biol. Psychiatry 72(4), 290–295 (2012).
   PubMed Web of Science ®Google Scholar
• Lee HC, Tsai SY, Lin HC. Seasonal variations in bipolar-disorder admissions and the association with climate: a population-based study. J. Affect Disord. 97(1–3), 61–69 (2007).
   PubMed Web of Science ®Google Scholar
• Cassidy F, Carroll BJ. Seasonal variation of mixed and pure episodes of bipolar disorder. J. Affect. Disord. 68(1), 25–31 (2002).
   PubMed Web of Science ®Google Scholar
• Dickerson F, Stallings C, Origoni A et al. Markers of gluten sensitivity and celiac disease in bipolar disorder. Bipolar Disord. 13(1), 52–58 (2011).
   PubMed Web of Science ®Google Scholar
• Post RM, Leverich GS. The role of psychosocial stress in the onset and progression of bipolar disorder and its comorbidities: the need for earlier and alternative modes of therapeutic intervention. Dev. Psychopathol. 18(4), 1181–1211 (2006).
   PubMed Web of Science ®Google Scholar
• Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc. Natl Acad. Sci. USA 104(4), 1319–1324 (2007).
   PubMed Web of Science ®Google Scholar
• McDade TW, Hawkley LC, Cacioppo JT. Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: the Chicago health, aging, and social relations study. Psychosom. Med. 68(3), 376–381 (2006).
   PubMed Web of Science ®Google Scholar
• Miller GE, Rohleder N, Cole SW. Chronic interpersonal stress predicts activation of pro- and anti-inflammatory signaling pathways 6 months later. Psychosom. Med. 71(1), 57–62 (2009).
   Google Scholar
• Spitzer C, Barnow S, Völzke H et al. Association of posttraumatic stress disorder with low-grade elevation of C-reactive protein: evidence from the general population. J. Psychiatr. Res. 44(1), 15–21 (2010).
   PubMed Web of Science ®Google Scholar
• von Känel R, Hepp U, Kraemer B et al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J. Psychiatr. Res. 41(9), 744–752 (2007).
   PubMedGoogle Scholar
• Pace TW, Mletzko TC, Alagbe O et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 163(9), 1630–1633 (2006).
   PubMed Web of Science ®Google Scholar
• Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th Century. Am. J. Clin. Nutr. 93(5), 950–962 (2011).
   PubMed Web of Science ®Google Scholar
• Kelley DS, Taylor PC, Nelson GJ, Mackey BE. Arachidonic acid supplementation enhances synthesis of eicosanoids without suppressing immune functions in young healthy men. Lipids 33(2), 125–130 (1998).
   PubMed Web of Science ®Google Scholar
• Song C, Li X, Leonard BE, Horrobin DF. Effects of dietary n-3 or n-6 fatty acids on interleukin-1β-induced anxiety, stress, and inflammatory responses in rats. J. Lipid Res. 44(10), 1984–1991 (2003).
   PubMed Web of Science ®Google Scholar
• Song C, Manku MS, Horrobin DF. Long-chain polyunsaturated fatty acids modulate interleukin-1β-induced changes in behavior, monoaminergic neurotransmitters, and brain inflammation in rats. J. Nutr. 138(5), 954–963 (2008).
   PubMed Web of Science ®Google Scholar
• Kelley DS, Taylor PC, Nelson GJ, Schmidt PC, Mackey BE, Kyle D. Effects of dietary arachidonic acid on human immune response. Lipids 32(4), 449–456 (1997).
   Google Scholar
• Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296(15), 1885–1899 (2006).
   PubMed Web of Science ®Google Scholar
• Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor-α and interleukin-1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am. J. Clin. Nutr. 63(1), 116–122 (1996).
   PubMed Web of Science ®Google Scholar
• Endres S, Ghorbani R, Kelley VE et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med. 320(5), 265–271 (1989).
   PubMed Web of Science ®Google Scholar
• Meydani SN, Endres S, Woods MM et al. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J. Nutr. 121(4), 547–555 (1991).
   PubMed Web of Science ®Google Scholar
• Lopez-Garcia E, Schulze MB, Manson JE et al. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J. Nutr. 134(7), 1806–1811 (2004).
   PubMed Web of Science ®Google Scholar
• Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 108(2), 155–160 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrucci L, Cherubini A, Bandinelli S et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J. Clin. Endocrinol. Metab. 91(2), 439–446 (2006).
   PubMed Web of Science ®Google Scholar
• Micallef MA, Munro IA, Garg ML. An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals. Eur. J. Clin. Nutr. 63(9), 1154–1156 (2009).
   PubMed Web of Science ®Google Scholar
• Farzaneh-Far R, Harris WS, Garg S, Na B, Whooley MA. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis 205(2), 538–543 (2009).
   PubMed Web of Science ®Google Scholar
• Tartibian B, Maleki BH, Abbasi A. Omega-3 fatty acids supplementation attenuates inflammatory markers after eccentric exercise in untrained men. Clin. J. Sport Med. 21(2), 131–137 (2011).
   PubMed Web of Science ®Google Scholar
• Ranjekar PK, Hinge A, Hegde MV et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 121(2), 109–122 (2003).
   PubMed Web of Science ®Google Scholar
• Hibbeln JR. Fish consumption and major depression. Lancet 351(9110), 1213 (1998).
   PubMed Web of Science ®Google Scholar
• Hibbeln JR. Seafood consumption, the DHA content of mothers’ milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J. Affect. Disord. 69(1–3), 15–29 (2002).
   PubMed Web of Science ®Google Scholar
• Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am. J. Psychiatry 160(12), 2222–2227 (2003).
   PubMed Web of Science ®Google Scholar
• Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. Br. J. Psychiatry 184, 404–408 (2004).
   PubMed Web of Science ®Google Scholar
• Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am. J. Clin. Nutr. 91(3), 757–770 (2010).
   PubMed Web of Science ®Google Scholar
• Freeman MP, Hibbeln JR, Wisner KL et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 67(12), 1954–1967 (2006).
   PubMed Web of Science ®Google Scholar
• Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 68(7), 1056–1061 (2007).
   PubMed Web of Science ®Google Scholar
• Stoffel W, Holz B, Jenke B et al. ∆6-desaturase (FADS2) deficiency unveils the role of omega-3- and omega-6-polyunsaturated fatty acids. EMBO J. 27(17), 2281–2292 (2008).
   PubMedGoogle Scholar
• Obukowicz MG, Welsch DJ, Salsgiver WJ et al. Novel, selective ∆6 or ∆5 fatty acid desaturase inhibitors as anti-inflammatory agents in mice. J. Pharmacol. Exp. Ther. 287(1), 157–166 (1998).
   PubMed Web of Science ®Google Scholar
• Merino DM, Ma DW, Mutch DM. Genetic variation in lipid desaturases and its impact on the development of human disease. Lipids Health Dis. 9, 63 (2010).
   PubMed Web of Science ®Google Scholar
• Do HJ, Chung HK, Moon J, Shin MJ. Relationship between the estimates of desaturase activities and cardiometabolic phenotypes in Koreans. J. Clin. Biochem. Nutr. 49(2), 131–135 (2011).
   Google Scholar
• Martinelli N, Girelli D, Malerba G et al. FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am. J. Clin. Nutr. 88(4), 941–949 (2008).
   PubMed Web of Science ®Google Scholar
• Standl M, Sausenthaler S, Lattka E et al.; GINIplus and LISAplus Study Group. FADS gene variants modulate the effect of dietary fatty acid intake on allergic diseases in children. Clin. Exp. Allergy 41(12), 1757–1766 (2011).
   Google Scholar
• Yu G, Björkstén B. Polyunsaturated fatty acids in school children in relation to allergy and serum IgE levels. Pediatr. Allergy Immunol. 9(3), 133–138 (1998).
   PubMedGoogle Scholar
• Malerba G, Schaeffer L, Xumerle L et al. SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease. Lipids 43(4), 289–299 (2008).
   PubMed Web of Science ®Google Scholar
• Marquardt A, Stöhr H, White K, Weber BH. cDNA cloning, genomic structure, and chromosomal localization of three members of the human fatty acid desaturase family. Genomics 66(2), 175–183 (2000).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Shen J, Abecasis GR et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI study. PLoS Genet. 5(1), e1000338 (2009).
   PubMed Web of Science ®Google Scholar
• Stafford AN, Rider SH, Hopkin JM, Cookson WO, Monaco AP. A 2.8 Mb YAC contig in 11q12-q13 localizes candidate genes for atopy: Fc epsilon RI β and CD20. Hum. Mol. Genet. 3(5), 779–785 (1994).
   Google Scholar
• Chapman K, Mustafa Z, Irven C et al. Osteoarthritis-susceptibility locus on chromosome 11q, detected by linkage. Am. J. Hum. Genet. 65(1), 167–174 (1999).
   PubMed Web of Science ®Google Scholar
• Daniels SE, Bhattacharrya S, James A et al. A genome-wide search for quantitative trait loci underlying asthma. Nature 383(6597), 247–250 (1996).
   PubMed Web of Science ®Google Scholar
• Palmer LJ, Daniels SE, Rye PJ et al. Linkage of chromosome 5q and 11q gene markers to asthma-associated quantitative traits in Australian children. Am. J. Respir. Crit. Care Med. 158(6), 1825–1830 (1998).
   Google Scholar
• Aulchenko YS, Ripatti S, Lindqvist I et al.; ENGAGE Consortium. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 41(1), 47–55 (2009).
   PubMed Web of Science ®Google Scholar
• Fallin MD, Lasseter VK, Wolyniec PS et al. Genome-wide linkage scan for bipolar-disorder susceptibility loci among Ashkenazi Jewish families. Am. J. Hum. Genet. 75(2), 204–219 (2004).
   PubMed Web of Science ®Google Scholar
• Liu Y, McNamara RK. Elevated ∆6-desaturase (FADS2) gene expression in the prefrontal cortex of patients with bipolar disorder. J. Psychiatr. Res. 45(2), 269–272 (2011).
   Google Scholar
• Barbosa NR, Junqueira RM, Vallada HP, Gattaz WF. Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 257(6), 340–343 (2007).
   PubMedGoogle Scholar
• Dikeos DG, Papadimitriou GN, Souery D et al. Lack of genetic association between the phospholipase A2 gene and bipolar mood disorder in a European multicentre case–control study. Psychiatr. Genet. 16(4), 169–171 (2006).
   Google Scholar
• Meira-Lima I, Jardim D, Junqueira R, Ikenaga E, Vallada H. Allelic association study between phospholipase A2 genes and bipolar affective disorder. Bipolar Disord. 5(4), 295–299 (2003).
   Google Scholar
• Pae CU, Yu HS, Kim JJ et al. BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. Neuropsychobiology 49(4), 185–188 (2004).
   Google Scholar
• Su KP, Huang SY, Peng CY et al. Phospholipase A2 and cyclooxygenase-2 genes influence the risk of interferon-α-induced depression by regulating polyunsaturated fatty acids levels. Biol. Psychiatry 67(6), 550–557 (2010).
   PubMed Web of Science ®Google Scholar
• Papiol S, Rosa A, Gutiérrez B et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J. Med. Genet. 41(3), 219–223 (2004).
   PubMedGoogle Scholar
• Czerski PM, Rybakowski F, Kapelski P et al. Association of tumor necrosis factor-308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 57(1–2), 88–94 (2008).
   PubMed Web of Science ®Google Scholar
• Pae CU, Lee KU, Han H, Serretti A, Jun TY. Tumor necrosis factor-α gene-G308A polymorphism associated with bipolar I disorder in the Korean population. Psychiatry Res. 125(1), 65–68 (2004).
   PubMed Web of Science ®Google Scholar
• Meira-Lima IV, Pereira AC, Mota GF et al. Analysis of a polymorphism in the promoter region of the tumor necrosis factor-α gene in schizophrenia and bipolar disorder: further support for an association with schizophrenia. Mol. Psychiatry 8(8), 718–720 (2003).
   PubMedGoogle Scholar
• Amminger GP, Schäfer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67(2), 146–154 (2010).
   PubMed Web of Science ®Google Scholar
• Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am. J. Psychiatry 163(6), 1098–1100 (2006).
   PubMed Web of Science ®Google Scholar
• Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 30(4), 497–521 (2009).
   PubMed Web of Science ®Google Scholar
• Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 50(2), 401–409 (2011).
   PubMed Web of Science ®Google Scholar
• Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised Phase III trial. Lancet 367(9504), 29–35 (2006).
   PubMed Web of Science ®Google Scholar
• Stolk P, Souverein PC, Leufkens HG, Weil JG, Egberts AC, Heerdink ER. The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case–control study. Pharmacopsychiatry 40(3), 111–115 (2007).
   PubMed Web of Science ®Google Scholar
• Elisa B, Beny L. Induction of manic switch by the tumour necrosis factor-α antagonist infliximab. Psychiatry Clin. Neurosci. 64(4), 442–443 (2010).
   Google Scholar
• Esposito G, Giovacchini G, Liow JS et al. Imaging neuroinflammation in Alzheimer’s disease with radiolabeled arachidonic acid and PET. J. Nucl. Med. 49(9), 1414–1421 (2008).
   PubMed Web of Science ®Google Scholar